Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 157

1.

Impact of BMI on serum estradiol and bone turnover markers in postmenopausal women with hormone-sensitive early breast cancer treated with anastrozole.

Kyvernitakis I, Knöll D, Struck M, Hars O, Bauer T, Hadji P.

J Cancer Res Clin Oncol. 2014 Jan;140(1):159-66. doi: 10.1007/s00432-013-1557-3. Epub 2013 Nov 29.

PMID:
24292402
2.

Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer.

Pfeiler G, Königsberg R, Hadji P, Fitzal F, Maroske M, Dressel-Ban G, Zellinger J, Exner R, Seifert M, Singer C, Gnant M, Dubsky P.

Br J Cancer. 2013 Sep 17;109(6):1522-7. doi: 10.1038/bjc.2013.499. Epub 2013 Sep 3.

3.

Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.

Confavreux CB, Fontana A, Guastalla JP, Munoz F, Brun J, Delmas PD.

Bone. 2007 Sep;41(3):346-52. Epub 2007 Jun 16.

PMID:
17618847
4.

Does obesity interfere with anastrozole treatment? Positive association between body mass index and anastrozole plasma levels.

Hubalek M, Oberguggenberger A, Beer B, Meraner V, Sztankay M, Oberacher H, Schubert B, Wildt L, Seeber B, Giesinger J, Kemmler G, Holzner B, Sperner-Unterweger B.

Clin Breast Cancer. 2014 Aug;14(4):291-6. doi: 10.1016/j.clbc.2013.12.008. Epub 2013 Dec 27.

PMID:
24468298
5.

Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer.

Folkerd EJ, Dixon JM, Renshaw L, A'Hern RP, Dowsett M.

J Clin Oncol. 2012 Aug 20;30(24):2977-80. doi: 10.1200/JCO.2012.42.0273. Epub 2012 Jul 16.

PMID:
22802308
6.
7.

A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer.

McCaig FM, Renshaw L, Williams L, Young O, Murray J, Macaskill EJ, McHugh M, Hannon R, Dixon JM.

Breast Cancer Res Treat. 2010 Feb;119(3):643-51. doi: 10.1007/s10549-009-0646-0.

PMID:
19941160
8.

Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors.

Lønning PE, Haynes BP, Dowsett M.

Eur J Cancer. 2014 Apr;50(6):1055-64. doi: 10.1016/j.ejca.2014.01.007. Epub 2014 Feb 4.

9.

Body mass index (BMI) and parameters of bone formation and resorption in postmenopausal women.

Papakitsou EF, Margioris AN, Dretakis KE, Trovas G, Zoras U, Lyritis G, Dretakis EK, Stergiopoulos K.

Maturitas. 2004 Mar 15;47(3):185-93.

PMID:
15036488
10.

Effect of anastrozole on hormone levels in postmenopausal women with early breast cancer.

Kyvernitakis I, Albert US, Kalder M, Winarno AS, Hars O, Hadji P.

Climacteric. 2015 Feb;18(1):63-8. doi: 10.3109/13697137.2014.929105. Epub 2014 Aug 17.

PMID:
24884402
11.

Systemic effects of conjugated equine estrogen vaginal cream on bone turnover markers in postmenopausal women.

Luengratsameerung S, Panyakhamlerd K, Treratanachat S, Taechakraichana N.

Climacteric. 2013 Feb;16(1):133-40. doi: 10.3109/13697137.2012.662252. Epub 2012 Apr 19.

PMID:
22515801
12.

Effect of aromatase inhibition on bone metabolism in elderly hypogonadal men.

Leder BZ, Finkelstein JS.

Osteoporos Int. 2005 Dec;16(12):1487-94. Epub 2005 Apr 23.

PMID:
15856361
13.

Serum concentrations of formation (PINP) and resorption (Ctx) bone turnover markers in rheumatoid arthritis.

Wisłowska M, Jakubicz D, Stepień K, Cicha M.

Rheumatol Int. 2009 Oct;29(12):1403-9. doi: 10.1007/s00296-009-0867-x. Epub 2009 Feb 15.

PMID:
19219607
15.

Effect of weight loss on bone health in overweight/obese postmenopausal breast cancer survivors.

Toriola AT, Liu J, Ganz PA, Colditz GA, Yang L, Izadi S, Naughton MJ, Schwartz AL, Wolin KY.

Breast Cancer Res Treat. 2015 Aug;152(3):637-43. doi: 10.1007/s10549-015-3496-y. Epub 2015 Jul 15.

16.

[Effects of anastrozole on lipid metabolism in Chinese postmenopausal women with breast cancer].

Lu HH, Li Q, Xu BH, Zhang P, Yuan P, Wang JY, Cai RG.

Zhonghua Zhong Liu Za Zhi. 2011 Jul;33(7):520-5. Chinese.

PMID:
22093630
17.

Aromatase inhibitors in obese breast cancer patients are not associated with increased plasma estradiol levels.

Diorio C, Lemieux J, Provencher L, Hogue JC, Vachon E.

Breast Cancer Res Treat. 2012 Nov;136(2):573-9. doi: 10.1007/s10549-012-2278-z. Epub 2012 Oct 6.

PMID:
23053662
18.

Efficacy of adjuvant aromatase inhibitor in hormone receptor-positive postmenopausal breast cancer patients according to the body mass index.

Sendur MA, Aksoy S, Zengin N, Altundag K.

Br J Cancer. 2012 Nov 20;107(11):1815-9. doi: 10.1038/bjc.2012.473. Epub 2012 Oct 25.

19.

Anastrozole: a review of its use in postmenopausal women with early-stage breast cancer.

Sanford M, Plosker GL.

Drugs. 2008;68(9):1319-40. Review.

PMID:
18547136
20.

Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer.

Dixon JM, Renshaw L, Young O, Murray J, Macaskill EJ, McHugh M, Folkerd E, Cameron DA, A'Hern RP, Dowsett M.

J Clin Oncol. 2008 Apr 1;26(10):1671-6. doi: 10.1200/JCO.2007.13.9279.

PMID:
18375896

Supplemental Content

Support Center